Sk Life Drug Patent Portfolio

Sk Life owns 1 orange book drug protected by 2 US patents Given below is the list of Sk Life's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11654133 Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy 16 Jun, 2039
Active
US7598279 Neurotherapeutic azole compounds 30 Oct, 2032
Active


Given below is the list of recent legal activities going on the following drug patents of Sk Life.

Activity Date Patent Number
Patent litigations
Electronic Review 07 Jun, 2024 US7598279
Mail Pub Notice re 312 amendment 20 Mar, 2024 US7598279
Email Notification 20 Mar, 2024 US7598279
Post Issue Communication - Certificate of Correction Denied 15 Mar, 2024 US7598279
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION 14 Mar, 2024 US7598279
Patent Term Extension Certificate 09 Nov, 2023 US7598279
Notice of Final Determination -Eligible 09 Aug, 2023 US7598279
FDA Final Eligibility Letter 13 Jul, 2023 US7598279
Recordation of Patent eGrant 23 May, 2023 US11654133
Recordation of Patent Grant Mailed 23 May, 2023 US11654133
Patent eGrant Notification 23 May, 2023 US11654133
Electronic Review 23 May, 2023 US11654133
Mail Patent eGrant Notification 23 May, 2023 US11654133
Patent Issue Date Used in PTA Calculation 23 May, 2023 US11654133
Email Notification 23 May, 2023 US11654133


Sk Life's Family Patents

Sk Life drugs have patent protection in a total of 19 countries. It's US patent count contributes only to 9.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Sk Life Drug List

Given below is the complete list of Sk Life's drugs and the patents protecting them.


1. Xcopri

Xcopri is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11654133 Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy 16 Jun, 2039
(14 years from now)
Active
US7598279 Neurotherapeutic azole compounds 30 Oct, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xcopri's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List